PD-1 和 PD-L1 抑制劑市場規模、佔有率、成長分析、按產品、按適應症、按分銷管道、按地區 - 產業預測，2024-2031 年

2022年全球PD-1和PD-L1抑制劑市場規模為468億美元，從2023年的551.8億美元成長到2031年的2060億美元，在預測期內（2024年-2031年）預計將以年複合成長率為17.9%。

在癌症發病率上升和免疫療法意識增強的推動下，PD-1 和 PD-L1 抑制劑市場正在經歷變革性成長。這些創新藥物針對免疫逃脫機制，並成功地使 T 細胞能夠對抗多種癌症，包括肺癌、黑色素瘤和膀胱癌。自2014年FDA核准Pembrolizumab （Keytruda）以來，已有多種抑制劑進入市場，包括nivolumab和Atezolizumab。北美地區目前因其強大的醫療基礎設施而領先市場，而亞太地區預計將隨著免疫療法意識的提高而成長。默克公司、羅氏公司和百時美施貴寶等大公司正在積極發展和建立夥伴關係。然而，隨著個人化醫療競爭的加劇，高昂的治療成本和副作用可能會限制市場擴張。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析

PD-1和PD-L1抑制劑依產品分類的市場規模

• 市場概況
• 納武單抗
• Pembrolizumab
• Atezolizumab
• Avelumab
• Durvalumab

按適應症分類的 PD-1 和 PD-L1 抑制劑市場規模

• 市場概況
• 惡性黑色素瘤
• 非小細胞肺癌（NSCLC）
• 腎臟細胞癌（RCC）
• 頭頸部鱗狀細胞癌 (HNSCC)
• 膀胱癌
• 默克細胞癌 (MCC)
• 其他

PD-1 和 PD-L1 抑制劑市場規模：按分銷管道分類

• 市場概況
• 醫院藥房
• 零售藥房
• 網路藥房

PD-1和PD-L1抑制劑市場規模（按地區）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• Akeso Inc.
• Alphamab Oncology
• Amgen Inc.
• AstraZeneca Plc
• BeiGene Ltd.
• Bristol Myers Squibb Co.
• Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Innovent Biologics Inc.
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Merck and Co. Inc.

結論和建議

Global PD-1 and PD-L1 Inhibitors Market size was valued at USD 46.8 billion in 2022 and is poised to grow from USD 55.18 billion in 2023 to USD 206.0 billion by 2031, growing at a CAGR of 17.9% during the forecast period (2024-2031).

The PD-1/PD-L1 inhibitor market has experienced transformative growth, driven by rising cancer prevalence and heightened awareness of immunotherapy. These innovative drugs target immune evasion mechanisms, successfully enabling T cells to combat various cancers, including lung, melanoma, and bladder cancers. Since the FDA's approval of pembrolizumab (Keytruda) in 2014, numerous inhibitors have entered the market, including nivolumab and atezolizumab. North America currently leads the market due to its robust healthcare infrastructure, but growth is anticipated in the Asia-Pacific region as awareness of immunotherapy rises. Key players like Merck, Roche, and Bristol-Myers Squibb are actively advancing development and forming partnerships. Nevertheless, high treatment costs and side effects could temper market expansion amidst emerging competition in personalized medicine.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pd-1 and Pd-L1 Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pd-1 and Pd-L1 Inhibitors Market Segmental Analysis

Global PD-1 and PD-L1 Inhibitors Market is segmented by product, indication, distribution channel and region. Based on product, the market is segmented into nivolumab, pembrolizumab, atezolizumab, avelumab and durvalumab. Based on indication, the market is segmented into melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck squamous cell cancer (HNSCC), bladder cancer, merkel cell carcinoma (MCC) and others. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pd-1 and Pd-L1 Inhibitors Market

The global PD-1 and PD-L1 inhibitors market is primarily driven by the escalating prevalence of cancer. With cancer positioned as the second leading cause of death worldwide, the World Health Organization projected approximately 12 million fatalities in 2022 alone. The notable effectiveness of PD-1 and PD-L1 inhibitors in treating diverse cancer types, including lung cancer, melanoma, and bladder cancer, underscores their importance in therapeutic applications. As the incidence of cancer continues to rise and the demand for efficient treatment alternatives grows, the PD-1 and PD-L1 inhibitors market is poised for significant expansion in response to these pressing healthcare needs.

Restraints in the Global Pd-1 and Pd-L1 Inhibitors Market

The global PD-1 and PD-L1 inhibitors market faces significant restraints primarily due to the high costs associated with these therapies. These inhibitors tend to be expensive, thereby restricting access for many patients, especially in developing regions. Moreover, the potential side effects-ranging from fatigue and nausea to diarrhoea-can further deter patients from opting for these advanced treatments. As a result, both healthcare providers and patients might gravitate towards more affordable alternatives like conventional chemotherapy. This situation not only imposes a financial strain on healthcare systems and insurance providers but also affects their willingness to reimburse the costs of these specialized drugs.

Market Trends of the Global Pd-1 and Pd-L1 Inhibitors Market

A significant trend shaping the global PD-1 and PD-L1 inhibitors market is the escalating emphasis on combination therapies. Recent studies indicate that integrating PD-1/PD-L1 inhibitors with other therapeutic modalities, such as chemotherapy or alternative immunotherapies, can markedly enhance treatment efficacy and mitigate the potential for resistance development. Major market players are channeling substantial resources into the formulation and clinical testing of innovative combination regimens, reflecting a collective effort to optimize patient outcomes. This trend is poised to gain momentum in the ensuing years as the medical community endeavors to transcend the constraints associated with PD-1/PD-L1 inhibitors when used as standalone treatments.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global PD-1 and PD-L1 Inhibitors Market Size by Product & CAGR (2024-2031)

• Market Overview
• Nivolumab
• Pembrolizumab
• Atezolizumab
• Avelumab
• Durvalumab

Global PD-1 and PD-L1 Inhibitors Market Size by Indication & CAGR (2024-2031)

• Market Overview
• Melanoma
• Non-Small Cell Lung Cancer (NSCLC)
• Renal Cell Carcinoma (RCC)
• Head and Neck Squamous Cell Cancer (HNSCC)
• Bladder Cancer
• Merkel Cell Carcinoma (MCC)
• Others

Global PD-1 and PD-L1 Inhibitors Market Size by Distribution Channel & CAGR (2024-2031)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global PD-1 and PD-L1 Inhibitors Market Size & CAGR (2024-2031)

• North America (Product, Indication, Distribution Channel)
  • USA
  • Canada
• Europe (Product, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, By Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Akeso Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alphamab Oncology
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca Plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline Plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innovent Biologics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck and Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations